Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents
申请人:——
公开号:US20040235919A1
公开(公告)日:2004-11-25
Compounds represented by formula (I), as defined in the description, wherein R is a hydrogen atom or a methyl group and R1 is a group as defined in the specification, or a pharmaceutically acceptable salt thereof, are disclosed; the said compounds are useful in the treatment of cell proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.
[EN] PHENYLACETAMIDO- PYRAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS<br/>[FR] DERIVES PHENYLACETAMIDO-PYRAZOLE ET LEUR UTILISATION COMME AGENTS ANTITUMORAUX
申请人:PHARMACIA ITALIA SPA
公开号:WO2002048114A1
公开(公告)日:2002-06-20
Phenylacetamido-pyrazoles of Formula (I) and, more particularly, N-(5-cycloalkyl-1H-pyrazol-3-yl) phenylacetamido derivatives, optionally further substituted as reported in the description; or pharmaceutically acceptable salts thereof; are useful in the treatment of cell proliferative disorders, e.g.cancer, associated with an altered cell cycle dependent kinase activity. Formula (I).
Phenylacetamido-pyrazole derivatives and their use as antitumor agents
申请人:——
公开号:US20040019046A1
公开(公告)日:2004-01-29
Phenylacetamido-pyrazoles and, more particularly, N-(5-cycloalkyl-1H-pyrazol-3-yl)phenylacetamido derivatives, optionally further substituted as reported in the description; or pharmaceutically acceptable salts thereof; are useful in the treatment of cell proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.
The present invention is directed to novel kinase inhibitors of general formula (I) and pharmaceutically acceptable salts thereof, and to the use of the kinase inhibitors of general formula (I) for treating diseases or disorders in which tau phosphorylation and cell cycle regulation is implicated, such as Alzheimer's Disease and cancer.
Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
申请人:Pfizer Italia S.r.l.
公开号:EP1724270A2
公开(公告)日:2006-11-22
Compounds represented by formula (I), as defined in the description, wherein R is a hydrogen atom or a methyl group and R1 is a group as defined in the specification, or a pharmaceutically acceptable salt thereof, are disclosed; the said compounds are useful in the treatment of cell proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.